SFDA To Use Third-Party Verification For New Drug Approval
This article was originally published in PharmAsia News
Executive Summary
To improve crackdown on counterfeit drugs, China's State FDA has recently tried out third-party verification for new drug approval. According to the agency, a third-party organization detected western medicine components in a TCM drug sample which was submitted for new drug license application, leading to the decision that the treatment effectiveness was false. SFDA has implemented stricter approval for high-risk medicines such as TCM injections, multi-component biochemical injections, high-volume chemical injections and biological products after the frequent occurrence of injection safety incidents in recent years. Furthermore, because previous drug approval procedures mainly check applicant's documents, some companies even fake clinical trial data for new drug licenses. SFDA is considering implementing third-party evaluation and verification to overcome its technical and facilities limitations, as well as to ensure objectivity. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.